Elan Rejects Royalty's New Takeover Bid After Stock Buyback
Irish drugmaker Elan Corp. PLC rejected a revised, $11.25-per-share takeover offer from New York investment firm Royalty Pharma on Monday, saying that the bid substantially undervalues the company....To view the full article, register now.
Already a subscriber? Click here to view full article